Paydirt
JC
Insider

Justin Chakma

Chief Business Officer

Justin Chakma (Chief Business Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in SPRY. The largest single filing was $1.5M of SPRY (166,380 sh across 2 lots, as filed), executed Nov 12 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.5M
shares × price, as filed
Last traded
Nov 12 2025
Filed Nov 14 2025
Open performance→
Volume by month
$5.7M$2.8M$0Oct 2024Apr 2025Oct 2025Apr 2026Nov 2024 · sells $1.4MDec 2024 · sells $5.7MNov 2025 · sells $1.5M
Buys $0 Sells $8.6M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names
SPRY SPRY SPRY · 0 buys · 6 sells 6 filings
Recent filings
SPRYSALE ARS Pharmaceuticals, Inc. View filing → $1.5M
166,380 sh across 2 lots
Exec Nov 12 2025
Filed Nov 14 2025 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $1.8M
144,605 sh across 2 lots
Exec Dec 12 2024
Filed Dec 13 2024 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $658K
50,000 sh × $13.15
Exec Dec 10 2024
Filed Dec 12 2024 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $2.0M
144,640 sh across 3 lots
Exec Dec 4 2024
Filed Dec 6 2024 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $1.2M
90,000 sh across 2 lots
Exec Dec 2 2024
Filed Dec 4 2024 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $1.4M
100,000 sh across 3 lots
Exec Nov 25 2024
Filed Nov 27 2024 · 5:30 PM ET